No significant differences in red blood cell levels were observed, however. All patients in the study had JAK2 V617F mutations but only 12 had FVL mutations. The FVL mutations accounted for 5% of PV ...

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) Friday announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide ...

Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of ...

There also could be a rationale for ruxolitinib having more impact earlier in the disease process when patients have fewer ...

Expert Rev Mol Diagn. 2012;12(5):511-526. Fragment analysis discriminates PCR products based on size and is useful for the detection of mutations, such as insertions, deletions and duplications ...

gDepartment of Pathology and Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA, hStanford Cancer Institute, Stanford University School ...

[18] Factor V Leiden (12%) Factor V Leiden mutation is more resistant to activated protein C and therefore takes longer to switch off clotting. Clotting is tested in the presence and absence of ...

Tumour cells can escape the therapeutic effects of selective JAK2 inhibitors by mutation-independent transactivation of JAK2 by JAK1. Here, we used selective JAK2 inhibition as a model to test the ...

Hemoglobin synthesis in the developing erythroblasts requires iron-containing heme. While EPO allows survival of erythroid progenitors and early-stage erythroblasts by activating transcription of anti ...